

University of Groningen

Optimizing therapy in patients with atrial fibrillation and heart failure

Mulder, Bart Antonius

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2015

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Mulder, B. A. (2015). *Optimizing therapy in patients with atrial fibrillation and heart failure*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

OPTIMIZING THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE



rijksuniversiteit
 groningen

Optimizing therapy in patients with atrial fibrillation and heart failure

Bart Antonius Mulder

Optimizing therapy in patients with atrial fibrillation and heart failure

Financial support for the publication of this thesis by the following companies / institutes
is gratefully acknowledged:

University of Groningen, Groningen University Institute for Drug Exploration (GUIDE),
Bayer B.V., BIOTRONIK Nederland B.V., Boehringer Ingelheim B.V., Chipsoft B.V.,
Daiichi Sankyo Nederland B.V., Pfizer B.V., Sanofi-Aventis Nederland B.V., Sorin Group
Nederland N.V., St. Jude Medical Nederland B.V., Zoll B.V.

ISBN: 978-90-367-7854-1

ISBN: 978-90-367-7853-4 (Electronic)

Copyright © 2015, Bart A. Mulder

All rights reserved. No part of this publication may be reproduced, stored in a retrieval
system, or transmitted in any form or by any means – electronic, mechanically, by
photocopying, recording or otherwise – without express written permission from the
author and, when appropriate, the publisher holding the copyrights of the published
articles.



Cover design and layout by Claudia Arévalo
argo1983@gmail.com
<http://cmgonzalezarevalo.wix.com/layout>

Printed by Grafimedia Facilitair bedrijf RUG

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus, prof. dr. E. Sterken
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op
15 juni 2015 om 16:15 uur.

door
Bart Antonius Mulder
geboren op 10 april 1985
te Emmen

Promotores:

Prof. dr. I.C. van Gelder

Prof. dr. D.J. van Veldhuisen

Copromotor:

Dr. M. Rienstra

Beoordelingscommissie:

Prof. dr. R.A. de Boer

Prof. dr. P. Kirchhof

Prof. dr. U. Schotten

Paranimfen:

drs. H.E. Postema

mr. J. Baukema

Financial support by the Dutch Heart Foundation for the publication of this thesis is gratefully acknowledged.

Table of Contents

Chapter 1	Introduction	8
Therapy and outcome in patients with a preserved left ventricular function		
Chapter 2	Lenient versus Strict Rate Control in Patients with Atrial Fibrillation and Heart Failure: A post hoc analysis of the RACE II study. <i>Eur J Heart Fail. 2013;15:1311-8</i>	24
Chapter 3	Digoxin in patient with permanent atrial fibrillation: data from the RACE II study. <i>Heart Rhythm. 2014;11:1543-50</i>	41
Chapter 4	Role of Duration of Atrial Fibrillation and Cardiac Biomarkers in Risk Prediction in Permanent Atrial Fibrillation: Data from the RACE II study <i>Submitted</i>	58
Therapy and outcome in patients with a preserved versus reduced left ventricular function		
Chapter 5	Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. <i>Eur J Heart Fail 2012;14:1171-8.</i>	73
Chapter 6	Beta-blockers and Outcome in Heart Failure and Atrial Fibrillation: A Meta-Analysis. <i>JACC Heart Fail.2013;1:21-28.</i>	91
Therapy and outcome in patients with a reduced left ventricular function		
Chapter 7	Cardiac resynchronization therapy in patients with and without atrial fibrillation. <i>Submitted</i>	108
Chapter 8	Discussion and future perspectives	126
Appendices:	Nederlandse samenvatting	159
	Acknowledgments	163
	Bibliography	167
	Biography	170